TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+24.49%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.63B
AUM Growth
+$415M
(+19%)
Cap. Flow
+$6.14M
Cap. Flow
% of AUM
0.23%
Top 10 Holdings %
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6
Top Buys
| 1 |
AbbVie
ABBV
|
$18.9M |
| 2 |
UnitedHealth
UNH
|
$15.7M |
| 3 |
Moderna
MRNA
|
$15.3M |
| 4 |
CVS Health
CVS
|
$14.4M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$10.6M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$28M |
| 2 |
Biogen
BIIB
|
$26.5M |
| 3 |
Gilead Sciences
GILD
|
$23.6M |
| 4 |
Illumina
ILMN
|
$18.8M |
| 5 |
Cigna
CI
|
$11.8M |
Sector Composition
| 1 | Healthcare | 95.26% |
| 2 | Real Estate | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zoetis
ZTS
$67.6B
| $11.1M | 0.42% |
81,121
-70,831
| -47% | -$9.71M |
|
52
Elevance Health
ELV
$70.7B
| $10.6M | 0.4% |
40,242
-25,326
| -39% | -$6.66M |
|
53
Welltower
WELL
$112B
| $10.5M | 0.4% |
203,083
| – | – |
|
54
Baxter International
BAX
$12.5B
| $10.5M | 0.4% |
122,023
+24,840
| +26% | +$2.14M |
|
55
argenx
ARGX
$45.9B
| $10.1M | 0.39% |
44,977
| – | – |
|
56
Agios Pharmaceuticals
AGIO
$2.11B
| $10M | 0.38% |
186,964
| – | – |
|
57
Teva Pharmaceuticals
TEVA
$21.6B
| $9.69M | 0.37% |
785,851
| – | – |
|
58
Allogene Therapeutics
ALLO
$257M
| $9.25M | 0.35% |
216,069
-28,192
| -12% | -$1.21M |
|
|
BPMC
59
DELISTED
Blueprint Medicines
BPMC
| $9.22M | 0.35% |
118,256
-21,080
| -15% | -$1.64M |
|
60
Omega Healthcare
OHI
$12.7B
| $9.11M | 0.35% |
306,433
| – | – |
|
|
MRTX
61
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9M | 0.34% |
78,784
| – | – |
|
62
GSK
GSK
$81.2B
| $8.99M | 0.34% |
176,210
+10,716
| +6% | +$546K |
|
63
Novo Nordisk
NVO
$245B
| $8.78M | 0.33% |
268,010
| – | – |
|
|
DOC
64
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $8.69M | 0.33% |
495,733
| – | – |
|
65
Ascendis Pharma
ASND
$12.5B
| $8.5M | 0.32% |
57,482
-11,850
| -17% | -$1.75M |
|
66
HCA Healthcare
HCA
$98.1B
| $8.14M | 0.31% |
83,833
| – | – |
|
67
Cencora
COR
$56.5B
| $8.13M | 0.31% |
80,645
+26,538
| +49% | +$2.67M |
|
|
RETA
68
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $7.94M | 0.3% |
50,907
+15,778
| +45% | +$2.46M |
|
69
FibroGen
FGEN
$48.7M
| $7.87M | 0.3% |
7,771
| – | – |
|
70
Labcorp
LH
$23.1B
| $7.85M | 0.3% |
55,000
+18,422
| +50% | +$2.63M |
|
71
NovoCure
NVCR
$1.36B
| $7.81M | 0.3% |
131,637
+24,199
| +23% | +$1.43M |
|
72
Medical Properties Trust
MPW
$2.75B
| $7.74M | 0.29% |
411,743
| – | – |
|
73
United Therapeutics
UTHR
$18B
| $7.69M | 0.29% |
63,513
| – | – |
|
74
Ultragenyx Pharmaceutical
RARE
$3.09B
| $7.63M | 0.29% |
97,480
| – | – |
|
75
Ventas
VTR
$30.9B
| $7.62M | 0.29% |
208,108
| – | – |
|